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1︿原著﹀
Computer-aided automated evaluation of MYB rearrangement 
in 10 cases of adenoid cystic carcinoma using fluorescent in situ 
hybridization: a single-institution study
Kenji Yorita1, Naoto Kuroda1, Yoshiko Agatsuma1, Yukari Wada1, Masahiko Ohara1,
 Kaori Yasuoka1, Keiko Mizuno1, Junya Fukuda2, Hideyuki Nakagawa2, Katsushi Miyazaki2, 
Nobuyuki Tanida3, Nobumasa Hamaguchi3
Abstract : 
Objective: The MYB-NFIB fusion gene has recently been detected in adenoid cystic carcinomas (ACCs) 
of the salivary gland and other organs. Detection of MYB rearrangement appears to be diagnostically 
valuable for ACCs, particularly in high-grade transformed ACCs (HGT-ACCs). However, a consensus 
cutoff value defining MYB rearrangement using fluorescence in situ hybridization (FISH) has not been 
established. The aim of this study was to investigate an appropriate evaluation of MYB rearrangement in 
ACCs using FISH. 
Study Design: We retrospectively selected 10 ACC cases diagnosed between 2000 and 2015. FISH 
analysis was performed using formalin-fixed paraffin-embedded sections and a MetaSystems image 
analysis system.
Results: The involved sites were the major salivary gland (n=4), oral cavity (n=2), lip (n=1), nasal cavity 
(n=1), external acoustic meatus (n=1), and trachea (n=1). One case was of HGT-ACC. Six cases (60%) 
including the HGT-ACC showed positive MYB rearrangement, exhibiting over 85% split MYB signals. 
The other cases were negative, demonstrating fewer than 10% split MYB signals, as observed in non-
neoplastic cells.
Conclusion: The MYB rearrangement cutoff value in ACC cells was 10%. MYB rearrangement 
heterogeneity in ACC cells appeared to not be present. This genetic study supported the diagnosis of 
HGT-ACC.
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1. Introduction
Adenoid cystic carcinoma (ACC) is the second 
most common malignant salivary gland tumor 
and accounts for <10% of all salivary gland 
neoplasms [1]. ACCs can arise in other sites, such 
as the ear canal, lacrimal glands, sinonasal tract, 
tracheobronchial tissue, breast, skin, and vulva 
[1, 2]. Conventional ACCs histologically consist of 
epithelial and myoepithelial tumor cells forming 
cribriform, tubular, and solid patterns. ACCs can 
undergo high-grade transformation characterized 
by cellular atypia beyond that of conventional 
ACC and loss of biphasic epithelial-myoepithelial 
architecture [3]. Histological diagnosis of high-
grade transformed ACC (HGT-ACC) is difficult, if 
the typical histological features of ACC cannot be 
detected. 
In 2009, Persson et al. identified a novel gene 
fusion in ACCs of the breast, head, and neck; 
recurrent translocation t(6;9)(q22-23;p23-24) involves 
the MYB oncogene and the transcription factor 
gene NFIB [4]. Such cytogenetic abnormality has 
also been detected in pulmonary ACCs [5] but has 
not been shown in other salivary gland tumors [4, 
6-8], invasive ductal carcinoma of the breast [4], or 
other histological subtypes of lung cancer [5]. Thus, 
the MYB-NFIB fusion gene has been postulated 
to be a tumor-specific cytogenetic abnormality 
of ACCs. Two studies have demonstrated with 
fluorescence in situ hybridization (FISH) that some 
HGT-ACCs exhibit MYB rearrangement [9, 10], 
suggesting that detection of this genetic event 
supports diagnosis of HGT-ACC. 
The MYB-NFIB gene fusion is evaluated by 
reverse transcriptase-polymerase chain reaction 
(RT-PCR) or FISH. MYB FISH in ACCs detects 
an unusual translocation of MYB, in addition to 
the one involving NFIB [11]; thus, MYB FISH may 
detect a broader range of MYB translocations 
than RT-PCR. However, MYB FISH studies on 
ACC have been limited [4-6, 9-14], and the rate 
of split MYB signals has not been determined in 
positive MYB rearrangement cases. Furthermore, 
no consensus cutof f  va lue def in ing MYB 
rearrangement in ACCs has been established using 
FISH, because cutoff values have differed in each 
study, ranging from 10% to 30% (and incidentally, 
the reasoning for selecting these values was not 
described) [9, 11, 12]. Thus, evaluation of ACC with 
MYB FISH may be problematic.
In the present study, we performed MYB FISH 
using formalin-fixed paraffin-embedded (FFPE) 
tissues from ACC cases diagnosed in our hospital 
and evaluated the cutoff value of split MYB signals 
defining positive MYB gene rearrangement. Split 
MYB signals were automatically interpreted using 
a MetaSystems image analysis system.
 
2. Materials and Methods
2.1 Consent
Comprehensive agreement for this study was 
obtained from all patients, and anonymized clinical 
information and pathological diagnosis were 
used for analyses. This study was conducted in 
accordance with the Declaration of Helsinki and 
was approved by the institutional review board of 
the Japanese Red Cross Kochi Hospital (No. 218).
2.2 ACC cases and classification
We retrospectively analyzed 10 cases of patients 
with ACC treated or diagnosed in our hospital 
between 2000 and 2015. Clinical information was 
obtained from medical records and included age, 
sex, tumor location, UICC stage at diagnosis, 
treatment, disease-free survival (DFS), and 
overall survival (OS). Surgically resected tumors 
were pathologically evaluated in 9 of the cases, 
and the other case (Case 8) was diagnosed by 
biopsy. Follow-up was performed from the date of 
surgery or biopsy to September 2017. Pathological 
data included maximum size (invasive depth), 
conventional ACC component grade, presence of 
HGT component, and perineural invasion. The 
growth patterns of ACCs are classified as tubular, 
cribriform, and solid [1]. Conventional ACC 
component grade was assessed according to the 
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Table 1. Clinicopathological and genetic data for the 10 cases of adenoid cystic carcinoma.
criteria developed by Szanto et al [15]: grade I was 
mostly tubular with some cribriform component, 
grade II was either entirely cribriform or tubular/
cribriform with a <30% solid component, and 
grade III had any growth pattern with a >30% 
solid component. The HGT component was 
assessed according to the description by Seethala 
et al [3].
2.3  FISH for MYB rearrangement and 
automated analysis of the FISH signals
FFPE tumor blocks used for pathological 
diagnosis were selected from each tumor, as 
the blocks included the largest cross-sectional 
slice of each tumor. Four-µm-thick sections 
were prepared from the FFPE tumor blocks for 
FISH analysis. ZytoLight SPEC MYB Dual Color 
Break Apart Probes (ZytoVision, Bremerhaven, 
Germany) were used. Pretreatment, hybridization, 
and posthybridization washes were performed 
according to the manufacturer ’ s protocols. 
Pretreatment and hybridization were performed 
with a VP-2000 Processor (Abbott Molecular, 
Tokyo, Japan) and a ThermoBrite system (Abbott 
Molecular), respectively. Fluorescence signals 
were automatically analyzed using the Metafer 
4 version 3.10.4 imaging system (MetaSystems 
GmbH, Altlussheim, Germany). At least 100 nuclei 
of tumor cells and 50 nuclei of background non-
tumor cells, such as endothelial cells, inflammatory 
cells, or fibroblasts, were scored in each case. 
Cells with two fusion signals (one orange and one 
green fluorochrome) were defined as normal. Cells 
harboring MYB rearrangements had one normal 
fusion signal, one orange signal, and one green 
signal.
2.4 Statistical analysis
The relationship between MYB rearrangement 
and clinical factors was evaluated by an unpaired 
t-test. All statistical analyses were performed with 
StatView version 5.0 (SAS Institute, Inc., Cary, NC, 
USA). Statistical significance was defined at p < 
0.05.
3. Results
Clinicopathological and genetic data from 
Table 1. Clinicopathological and genetic data for the 10 cases of adenoid cystic carcinoma. 
 
Abbreviations: M, male; F, female; NA, not available; PI, perineural invasion; Re, resection; Ra, radiotherapy; P, palliative care; DFS, disease-free 
survival; L, lost to follow-up; OS, overall survival; AWOD, alive without disease; AWD, alive with disease; FISH, fluorescent in situ hybridization. 
 
Case 
Age/ 
Sex 
Tumor location 
Conventional 
ACC grade  
High-grade 
transformed 
component 
Maximal size 
(invasive depth) 
PI 
UICC 
stage 
Treatment 
DFS/OS 
(mo.) 
MYB FISH  
(Split signal %) 
1 45/M Trachea 2 (-) NA (-) NA Re 43/43 (L) 96  
2 67/F Oral cavity 2 (-) 18 mm (8 mm) (-) T2N0M0 Re 
92/92 
(AWoD) 
98  
3 70/M Oral cavity 1 (-) 22 mm (11 mm) (+) NA Re 118/126 (L) 99  
4 73/M Lip 1 (-) 20 mm (11 mm) (+) T3N0M0 Re 43/43 (L) 86  
5 46/F Parotid gland Not found (+) 30 mm (+) T3N0M0 Re + Ra 
29/29 
(AWoD) 
92  
6 74/F Parotid gland 2 (-) 15 mm (-) T3N0M0 Re + Ra 
18/51 
(AWoD) 
99  
7 35/F Parotid gland 3 (-) 10 mm (-) T1N0M0 Re NA/NA 8  
8 87/F 
Submandibular 
gland 
2 (-) 38 mm (-) 
T3N0M1 
(lung) 
P 
None/28 
(AWD) 
9  
9 74/F Nasal cavity 2 (-) 27 mm (-) T3N0M0 Re 36/95 (AWD) 7  
10 56/F 
External acoustic 
meatus 
2 (-) 7 mm (-) 
T1N0M1 
(thigh) 
Re 
136/211 
(AWD) 
5  
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our cases are summarized in Table 1. Patient 
age ranged from 35 to 87 years, with a median 
(interquartile range, IQR) of 68 (46-74) years. 
Patients were predominately female, with a 
male to female ratio of 3:7. Tumor locations 
were as follows: major salivary gland (n=4), 
oral cavity (n=2), lip (n=1), nasal cavity (n=1), 
external acoustic meatus (n=1), and trachea (n=1). 
Conventional ACCs of grade I (n=2), grade II 
(n=6, Figure 1A–C), grade III (n=1) were found in 
nine of the cases. The other case (Case 5, Figure 
1D–F) was an HGT-ACC initially diagnosed as 
basal cell adenocarcinoma by histological and 
immunohistochemical studies. Perineural invasion 
was seen in three of the 10 cases, and distant 
metastases were observed in two of the 10 cases 
at diagnosis. Follow-up data were available for 
nine cases, and three of the nine cases were lost 
to follow-up. The median overall survival was 51 
months (IQR: 39-102 months), and no tumor-related 
death was observed.
In FISH analysis, six of the 10 cases (60%) 
including the HGT-ACC case showed a high rate (in 
>85% of cells) of split MYB signals (Figure 1C and 
F), which was considered to indicate positive MYB 
rearrangement. In contrast, four of the 10 cases 
(40%) showed spilt MYB signals in fewer than 10% 
of cells, similarly to the background non-tumor 
cells. Thus, the MYB rearrangement cutoff value 
was postulated to be 10%. No equivocal result was 
obtained. Neither the presence nor the absence of 
MYB rearrangement was significantly correlated 
Figure 1. Histological and fluorescence in situ hybridization findings for adenoid cystic carcinomas. 
A–C) Conventional adenoid cystic carcinoma (ACC). The tumor shows a cribriform growth of monomorphic tumor 
cells (A–B). Fluorescence in situ hybridization (FISH) of the MYB gene shows that most tumor cells have split 
signals (C). The inset in C is a magnified photo of the typical split signal indicated by an arrow. D–F) High-grade 
transformed ACC. The tumor shows solid (D) or trabecular (E) growth of atypical cells showing frequent mitosis 
(arrows in E). Central necrosis is seen in the solid nest (D). FISH demonstrates positive MYB gene rearrangement (F). 
The inset in F is a magnified photo of the typical split signal indicated by an arrow. A, B, D, and E are taken from 
sections stained with hematoxylin and eosin. Bars represent 50 µm.
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with age, sex, maximum tumor size, perineural 
invasion, DFS, or OS.
4. Discussion
Our study demonstrated FISH to be a useful 
tool for evaluating MYB rearrangement using 
FFPE ACC sections, with the ability to make such 
evaluations in FFPE blocks prepared more than 
17 years prior to analysis. Six of the 10 cases (60%) 
in our study were considered positive for MYB 
rearrangement, which is a rate consistent with 
that reported in previous studies (77/127 cases, 
61%) [11, 13, 14]. No equivocal cases were found 
using FISH; therefore, an additional molecular 
assay such as RT-PCR, was not required. As 
shown in our study, MYB-NFIB tumor status was 
not significantly associated with OS or DFS [16]. 
Our study is the first to show the rate of split 
MYB signals in positive MYB rearrangement 
cases. Our cases with positive MYB rearrangement, 
i .e . , f ive conventional ACCs and one HGT-
ACC, suggested that heterogeneity in MYB 
rearrangement was not present. Thus, FISH 
analysis using a biopsy sample can estimate MYB 
rearrangement of the whole tumor. However, 
Costa et al. reported that in one case of ACC 
with high-grade transformation, MYB-NFIB 
translocation only occurred in areas with the 
HGT component and not in the areas with only 
conventional components [9]. Thus, further genetic 
studies on heterogeneity in MYB rearrangements 
in ACCs are warranted. 
A high rate of split MYB signals in ACCs was 
obtained using the automated imaging analyzer. 
The automatically evaluated FISH data were 
preserved and can be reviewed retrospectively. 
Automatically analyzed data for the cancer 
tissues included that of tumor and non-tumor 
cells, such as endothelial cells, inflammatory cells, 
and fibroblasts. Non-tumor cell data could be 
retrospectively removed from the analyzed data, 
which may increase the rate of split MYB signals 
in the tumor cells. In contrast, the computer-aided 
analysis of the data may have reduced the cutoff 
value of split MYB signals compared to the 10 to 
30% reported in previous studies [9, 11, 12]. In our 
study, counting of split MYB signals in non-tumor 
cells supported the postulated cutoff value defining 
positive MYB rearrangement. However, further 
additional study for optimal cutoff value of split 
MYB signals in ACCs will be needed because the 
present study dealed with only 10 cases. 
One high-grade tumor (Case 5) was determined to 
be an HGT-ACC by positive MYB rearrangement, 
as basal cell adenocarcinoma has not been 
associated with positive MYB rearrangement 
[7]. Genetic studies of salivary gland HGT-
ACCs have been limited [9], and the rate of 
MYB rearrangement in HGT-ACCs may be low, 
considering that breast HGT-ACCs have shown 
low rates of MYB rearrangement (2/16 cases, 
12.5%) [10]. However, MYB FISH analysis of 
HGT-ACCs appears to be a viable option when 
conclusive diagnosis of such tumors cannot be 
obtained histologically or immunohistochemically.
5. Conclusions
Our automated analysis of MYB rearrangement 
in ACC cells using FFPE sections showed positive 
results in 60% of cases, and the cutoff value 
defining MYB rearrangement was postulated to 
be 10%. No heterogeneity of MYB rearrangement 
in ACC cells was present in our study. This 
genetic study supports the conclusive diagnosis of 
high-grade tumors.
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